178 related articles for article (PubMed ID: 26116627)
1. Spironolactone is secure and reduces left ventricular hypertrophy in hemodialysis patients.
Feniman-De-Stefano GM; Zanati-Basan SG; De Stefano LM; Xavier PS; Castro AD; Caramori JC; Barretti P; Franco RJ; Martin LC
Ther Adv Cardiovasc Dis; 2015 Aug; 9(4):158-67. PubMed ID: 26116627
[TBL] [Abstract][Full Text] [Related]
2. Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients.
Gross E; Rothstein M; Dombek S; Juknis HI
Am J Kidney Dis; 2005 Jul; 46(1):94-101. PubMed ID: 15983962
[TBL] [Abstract][Full Text] [Related]
3. Effect of spironolactone on diastolic function in hypertensive left ventricular hypertrophy.
Gupta A; Schiros CG; Gaddam KK; Aban I; Denney TS; Lloyd SG; Oparil S; Dell'Italia LJ; Calhoun DA; Gupta H
J Hum Hypertens; 2015 Apr; 29(4):241-6. PubMed ID: 25231508
[TBL] [Abstract][Full Text] [Related]
4. A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients.
Hammer F; Malzahn U; Donhauser J; Betz C; Schneider MP; Grupp C; Pollak N; Störk S; Wanner C; Krane V;
Kidney Int; 2019 Apr; 95(4):983-991. PubMed ID: 30712923
[TBL] [Abstract][Full Text] [Related]
5. Spironolactone in chronic hemodialysis patients improves cardiac function.
Taheri S; Mortazavi M; Shahidi S; Pourmoghadas A; Garakyaraghi M; Seirafian S; Eshaghian A; Ghassami M
Saudi J Kidney Dis Transpl; 2009 May; 20(3):392-7. PubMed ID: 19414940
[TBL] [Abstract][Full Text] [Related]
6. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial.
Edwards NC; Steeds RP; Stewart PM; Ferro CJ; Townend JN
J Am Coll Cardiol; 2009 Aug; 54(6):505-12. PubMed ID: 19643310
[TBL] [Abstract][Full Text] [Related]
7. A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome.
Kosmala W; Przewlocka-Kosmala M; Szczepanik-Osadnik H; Mysiak A; O'Moore-Sullivan T; Marwick TH
JACC Cardiovasc Imaging; 2011 Dec; 4(12):1239-49. PubMed ID: 22172779
[TBL] [Abstract][Full Text] [Related]
8. Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension.
Sato A; Suzuki Y; Saruta T
Hypertens Res; 1999 Mar; 22(1):17-22. PubMed ID: 10221346
[TBL] [Abstract][Full Text] [Related]
9. Effects of Spironolactone and Chlorthalidone on Cardiovascular Structure and Function in Chronic Kidney Disease: A Randomized, Open-Label Trial.
Edwards NC; Price AM; Mehta S; Hiemstra TF; Kaur A; Greasley PJ; Webb DJ; Dhaun N; MacIntyre IM; Farrah T; Melville V; Herrey AS; Slinn G; Wale R; Ives N; Wheeler DC; Wilkinson I; Steeds RP; Ferro CJ; Townend JN
Clin J Am Soc Nephrol; 2021 Oct; 16(10):1491-1501. PubMed ID: 34462286
[TBL] [Abstract][Full Text] [Related]
10. The Safety of Eplerenone in Hemodialysis Patients: A Noninferiority Randomized Controlled Trial.
Walsh M; Manns B; Garg AX; Bueti J; Rabbat C; Smyth A; Tyrwhitt J; Bosch J; Gao P; Devereaux PJ; Wald R
Clin J Am Soc Nephrol; 2015 Sep; 10(9):1602-8. PubMed ID: 26138259
[TBL] [Abstract][Full Text] [Related]
11. Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial.
Charytan DM; Himmelfarb J; Ikizler TA; Raj DS; Hsu JY; Landis JR; Anderson AH; Hung AM; Mehrotra R; Sharma S; Weiner DE; Williams M; DiCarli M; Skali H; Kimmel PL; Kliger AS; Dember LM;
Kidney Int; 2019 Apr; 95(4):973-982. PubMed ID: 30473139
[TBL] [Abstract][Full Text] [Related]
12. Regression of left ventricular hypertrophy in patients with primary aldosteronism/low-renin hypertension on low-dose spironolactone.
Ori Y; Chagnac A; Korzets A; Zingerman B; Herman-Edelstein M; Bergman M; Gafter U; Salman H
Nephrol Dial Transplant; 2013 Jul; 28(7):1787-93. PubMed ID: 23378418
[TBL] [Abstract][Full Text] [Related]
13. A prospective double-blind randomized placebo-controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis.
Taheri S; Mortazavi M; Pourmoghadas A; Seyrafian S; Alipour Z; Karimi S
Saudi J Kidney Dis Transpl; 2012 May; 23(3):507-12. PubMed ID: 22569436
[TBL] [Abstract][Full Text] [Related]
14. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Pitt B; Remme W; Zannad F; Neaton J; Martinez F; Roniker B; Bittman R; Hurley S; Kleiman J; Gatlin M;
N Engl J Med; 2003 Apr; 348(14):1309-21. PubMed ID: 12668699
[TBL] [Abstract][Full Text] [Related]
15. Management of resistant hypertension: aldosterone antagonists or intensification of diuretic therapy?
Verdalles U; García de Vinuesa S; Goicoechea M; Macías N; Santos A; Perez de Jose A; Verde E; Yuste C; Luño J
Nephrology (Carlton); 2015 Aug; 20(8):567-71. PubMed ID: 25818266
[TBL] [Abstract][Full Text] [Related]
16. Effects of spironolactone-altizide on left ventricular hypertrophy.
Degre S; Detry JM; Unger P; Cosyns J; Brohet C; Kormoss N
Acta Cardiol; 1998; 53(5):261-7. PubMed ID: 9922803
[TBL] [Abstract][Full Text] [Related]
17. Research Progress on the Efficacy and Safety of Spironolactone in Reversing Left Ventricular Hypertrophy in Hemodialysis Patients.
Sun Z; Chen Z; Liu R; Lu G; Li Z; Sun Y
Drug Des Devel Ther; 2023; 17():181-190. PubMed ID: 36712946
[TBL] [Abstract][Full Text] [Related]
18. Randomized, double-blind, placebo-controlled trial of spironolactone for hypokalemia in continuous ambulatory peritoneal dialysis patients.
Yongsiri S; Thammakumpee J; Prongnamchai S; Tengpraettanakorn P; Chueansuwan R; Tangjaturonrasme S; Dinchuthai P
Ther Apher Dial; 2015 Feb; 19(1):81-6. PubMed ID: 25196890
[TBL] [Abstract][Full Text] [Related]
19. Review article: eplerenone: an underused medication?
Abuannadi M; O'Keefe JH
J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):318-25. PubMed ID: 20876342
[TBL] [Abstract][Full Text] [Related]
20. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure.
Mottram PM; Haluska B; Leano R; Cowley D; Stowasser M; Marwick TH
Circulation; 2004 Aug; 110(5):558-65. PubMed ID: 15277317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
